Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia.
antibodies
artemisinin
malaria
parasite
resistance
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
received:
10
02
2022
accepted:
12
06
2022
pubmed:
16
6
2022
medline:
27
8
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2-7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, -0.14 to +0.40 hour) in DRC patients. In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.
Sections du résumé
BACKGROUND
Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified.
METHODS
In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere.
RESULTS
Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2-7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, -0.14 to +0.40 hour) in DRC patients.
CONCLUSIONS
In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.
Identifiants
pubmed: 35703955
pii: 6608717
doi: 10.1093/infdis/jiac232
pmc: PMC9400417
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-331Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Proc Biol Sci. 2015 Feb 22;282(1801):20142657
pubmed: 25567652
Lancet Infect Dis. 2021 Apr;21(4):e82-e92
pubmed: 33125913
Infect Immun. 2005 Apr;73(4):2116-22
pubmed: 15784553
Parasitology. 2018 Jun;145(7):839-847
pubmed: 29144217
J Immunol. 2013 Jul 15;191(2):795-809
pubmed: 23776179
Malar J. 2015 Sep 22;14:359
pubmed: 26390866
Malar J. 2016 Jan 06;15:10
pubmed: 26739092
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60
pubmed: 16438676
J Infect Dis. 2015 Jan 15;211(2):290-7
pubmed: 25183768
J Infect Dis. 2013 Jun 1;207(11):1655-63
pubmed: 23448727
Lancet Infect Dis. 2021 Aug;21(8):1120-1128
pubmed: 33864801
Malar J. 2021 Jul 16;20(1):319
pubmed: 34271941
J Infect Dis. 2019 Aug 30;220(7):1178-1187
pubmed: 31075171
Nat Med. 2020 Oct;26(10):1602-1608
pubmed: 32747827
Blood. 1997 Sep 1;90(5):2037-40
pubmed: 9292540
N Engl J Med. 2018 Nov 15;379(20):1962-1964
pubmed: 30428283
Immunol Rev. 2020 Jan;293(1):8-24
pubmed: 31840836
Immunity. 2015 Mar 17;42(3):580-90
pubmed: 25786180
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520
pubmed: 28289193
J Infect Dis. 2017 Sep 15;216(6):723-731
pubmed: 28934435
PLoS Biol. 2015 Apr 22;13(4):e1002132
pubmed: 25901609
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Blood. 2001 Jul 15;98(2):450-7
pubmed: 11435316
Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents
pubmed: 19136431
J Infect Dis. 2019 Apr 16;219(9):1483-1489
pubmed: 30657916
Elife. 2016 Mar 04;5:
pubmed: 26943619
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Malar J. 2011 Nov 10;10:339
pubmed: 22074219
J Clin Invest. 2012 Sep;122(9):3227-38
pubmed: 22850879
BMC Med. 2018 Apr 30;16(1):61
pubmed: 29706136
Antimicrob Agents Chemother. 1997 Jul;41(7):1413-22
pubmed: 9210658
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Parasit Vectors. 2014 Jun 09;7:265
pubmed: 24912923
BMC Med. 2019 Jan 17;17(1):1
pubmed: 30651111
Blood. 2011 Jan 13;117(2):381-92
pubmed: 20852127
Acta Trop. 2012 Mar;121(3):227-39
pubmed: 21382335
N Engl J Med. 2021 Sep 23;385(13):1163-1171
pubmed: 34551228
J Infect Dis. 2015 Mar 1;211(5):670-9
pubmed: 25180241
J Infect Dis. 2002 May 15;185(10):1538-41
pubmed: 11992295